CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy Other Tyrosine Kinase Inhibitors Chemotherapy EGFR DNA Serine-Threonine Kinase Inhibitors Cyclin Dependent Kinase Inhibitors MDM2/MDMX Threonine-Tyrosine Kinase Inhibitors PI3 Kinase Inhibitors Epigenetics | Non Small Cell Lung Cancer | Lung Non-Squamous Non-Small Cell Cancer | Lung Adenocarcinoma | Solid Tumor | Pituitary Gland Carcinoma | Pancreatic Cancer | Lung Cancer | Lung Non-Small Cell Squamous Cancer | Cervical Cancer |
---|---|---|---|---|---|---|---|---|---|
bevacizumab + atezolizumab | |||||||||
pembrolizumab + BGB324 | |||||||||
durvalumab + tremelimumab | |||||||||
everolimus | |||||||||
camrelizumab + rivoceranib | |||||||||
BGB324 | |||||||||
abemaciclib | |||||||||
TNG260 | |||||||||
DRP-104 | |||||||||
pembrolizumab + ramucirumab | |||||||||
Immunotherapy | |||||||||
temozolomide + capecitabine | |||||||||
pembrolizumab | |||||||||
APG-115 | |||||||||
dasatinib + selumetinib + RTB101 | |||||||||
dasatinib | |||||||||
sirolimus | |||||||||
CI-1040 | |||||||||
nivolumab | |||||||||
JQ-1 | |||||||||
durvalumab | |||||||||
ABCP | |||||||||
docetaxel | |||||||||
atezolizumab | |||||||||
PD-L1 inhibitor | |||||||||
cetuximab + avelumab | |||||||||
anlotinib + sintilimab |